Landscape analysis of oncology nutrition research among patients being treated for cancer

THE GEORGE WASHINGTON UNIVERSITY WASHINGTON, DC



3. Parsons HM, et al. JNCI Cancer Spectr 2023;7(3):pkad035. PMID: 37212631

Kim Robien^{1,2}, Heather Wopat¹

¹Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health; ²GW Cancer Center George Washington University, Washington, DC, USA krobien@gwu.edu

	Results				
e 1. Characteristics of the included studies Table 2. Characteristics of completed studies by					
	Intervention studies Observational studies publication status (as of December 2023)				
racteristic	n=273	n=70		Published	Not published
	n (%)	n (%)	Characteristic	n=35	n=84
ly status (as of January 2023)				n (%)	n (%)
ot yet recruiting	38 (13.9)	7 (10.0)	Study design		
cruiting	69 (25.3)	16 (22.9)	Intervention study	31 (88.6)	63 (75.0)
mpleted	94 (34.4)	25 (35.7)	Observational study	4 (11.4)	21 (25.0)
spended, terminated or withdrawn	24 (8.8)	5 (7.1)	Cancer site		
known status	46 (16.8)	17 (24.3)	Breast	2 (5.7)	10 (11.9)
vention/exposure			Colorectal	6 (17.1)	8 (9.5)
etary supplements	107 (39.2)	9 (12.9)	Esophageal	2 (5.7)	8 (9.5)
et in conjunction with a drug trial	46 (16.8)	3 (4.3)	Head and neck	4 (11.4)	5 (6.0)
havioral interventions	39 (14.3)	5 (7.1)	Prostate	1 (2.9)	7 (8.3)
sting-mimicking, time-restricted feeding	11 (4.0)	1 (1.4)	Lung	1 (2.9)	7 (8.3)
togenic diet	13 (4.8)	0	Gastric	2 (5.7)	2 (2.4)
od security status	1 (0.4)	1 (1.4)	Ovarian	1 (2.9)	2 (2.4)
come measures			Neuroendocrine	0	3 (3.6)
asibility	21 (7.7)	3 (4.3)	Lymphoma	0	3 (3.6)
herence	20 (7.3)	2 (2.9)	Leukemia	0	2 (2.4)
verse Events	70 (25.5)	16 (22.9)	Brain	2 (5.7)	0
ality of life	103 (37.7)	14 (20.0)	Bladder	0	2 (2.4)
tigue	13 (4.8)	1 (1.4)	Myeloma	0	1 (1.2)
eight/body composition change,	125 (45 8)	19 (27 1)	Intervention/exposure		
sarcopenia	120 (40.0)	10 (27.1)	Dietary supplements	10 (28.6)	35 (41.7)
crobiome alteration	18 (6.6)	4 (5.7)	Fasting-mimicking diet,	2(0, c)	(0, 4)
currence	3 (1.1)	0	time-restricted feeding	3 (0.0)	Z (Z.4)
rvival	50 (18.2)	13 (18.6)	Ketogenic diet	1 (2.9)	1 (1.2)
st	10 (3.6)	2 (2.9)	Study location	·	
ly location			US	3 (8.6)	20 (23.8)
5	66 (24.2)	9 (12.9)	Non-US	32 (91.4)	64 (76.2)
n-US	207 (75.8)	61 (87.1)	Study funding		
y funding (not mutually exclusive)		Industry	5 (14.3)	10 (11.9)	
lustry	26 (9.5)	4 (5.7)	NIH	2 (5.7)	5 (6.0)
	20 (7.3)	1 (1.4)	Other	34 (97.1)	82 (97.6)
her	265 (97.1)	68 (97.1)			

Summary of the findings

• Similar to the AHRQ review³, this project found that more oncology nutrition research is being conducted outside of the US than within the US. • Most common outcomes: changes in body weight/composition (n=144), quality of life (n=117), adverse events (n=86), and survival (n=63).

• Of the 119 studies marked as completed, only 35 (29.4%) had at least one article (mean: 1.3, range: 1-3) listed in PubMed as of December 2023.

Conclusions

More research is needed to support development of evidence-based oncology nutrition clinical practice guidelines. US federal funding agencies should prioritize rigorous oncology nutrition research with outcomes applicable to clinical practice. Additionally, efforts should be made to support researchers in completing studies and disseminating research findings, including studies with "null" results.

Milken Institute School of Public Health

THE GEORGE WASHINGTON UNIVERSITY

GW

Cancer Center

Limitations

- Data in ClinicalTrials.gov is largely entered by study investigators, often as open text without standardization.
- ClinicalTrials.gov listings may not be complete, accurate or current.
- Investigators do not always include NCT numbers in research publications, thus we may not have identified all associated publications
- Unable to evaluate quality/rigor of the individual studies.